IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Blood and marrow transplantation in the People′s Republic of China
Wu, T.2; Lu, D-P1,2
关键词Unrelated Haploidentical Sct
刊名BONE MARROW TRANSPLANTATION
2008-08-01
DOI10.1038/bmt.2008.123
suppl.1页:S73-S75
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
英文摘要

Syngeneic BMT was first performed successfully in China in 1964. In 1981, allogeneic BMT was applied in an acute leukemia patient with success. Since then, the number of BMTs has been increasing gradually, especially since the 1990s. More than 2000 stem cell transplants per year have been performed in recent years in more than 50 BMT units in mainland China. A survey of 16 BMT units from 1986 to 2005 indicates that the predominant types of transplantation performed are identical sibling (36%), related mismatched/haploidentical (11.2%), unrelated (7.5%) and autologous (44.5%) and that the distribution of disease entities and prevalent diseases being transplanted are AML (31%), ALL (16.1%), CML (19.1%) and lymphoid malignancy (22.2%). The number of transplants from unrelated donor or related mismatched/haploidentical donor has increased significantly in the past 5 years. BM and G-CSF-mobilized peripheral blood are used about equally often as a source of hematopoietic stem cells, or they are used in combination. Umbilical cord blood is used least often. Leukemias for allogeneic and lymphoid malignancies for autologous BMT continue to increase, but the increase in BMT for CML has been slow since 2004. By the end of 2007, HLA data were available on more than 700 000 individuals in the Chinese Marrow Donor Program, and 800 stem cell donations have been carried out from these. Related HLA-mismatched/haploidentical BMT has achieved comparable outcomes in terms of severe acute GVHD, chronic GVHD, relapse, treatment-related mortality, disease-free survival (DFS) and overall survival (OS) with HLA-identical sibling transplantation in the author′s two BMT units. Cord blood co-infusion as the third-party cells could significantly reduce the incidence and severity of acute GVHD, steroid-refractory acute GVHD and extensive chronic GVHD without an increase in leukemia relapse and could improve DFS and OS.

语种英语
WOS记录号WOS:000258444900022
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52549
专题北京大学第二临床医学院
作者单位1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Beijing Daopei Hosp, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Wu, T.,Lu, D-P. Blood and marrow transplantation in the People′s Republic of China[J]. BONE MARROW TRANSPLANTATION,2008,suppl.1:S73-S75.
APA Wu, T.,&Lu, D-P.(2008).Blood and marrow transplantation in the People′s Republic of China.BONE MARROW TRANSPLANTATION,suppl.1,S73-S75.
MLA Wu, T.,et al."Blood and marrow transplantation in the People′s Republic of China".BONE MARROW TRANSPLANTATION suppl.1(2008):S73-S75.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wu, T.]的文章
[Lu, D-P]的文章
百度学术
百度学术中相似的文章
[Wu, T.]的文章
[Lu, D-P]的文章
必应学术
必应学术中相似的文章
[Wu, T.]的文章
[Lu, D-P]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。